scholarly journals NGHIÊN CỨU GIÁ TRỊ CỦA 18FDG PET/CT DỰ ĐOÁN TÌNH TRẠNG ĐỘT BIẾN GEN EGFR Ở BỆNH NHÂN UNG THƯ PHỔI BIỂU MÔ TUYẾN

2022 ◽  
Vol 509 (1) ◽  
Author(s):  
Bùi Tiến Công ◽  
Phạm Văn Thái ◽  
Phạm Cẩm Phương ◽  
Đồng Thị Hằng ◽  
Phạm Văn Tuyến ◽  
...  
Keyword(s):  
Fdg Pet ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

Mục tiêu nghiên cứu: Nghiên cứu giá trị của FDG PET/CT dự đoán tình trạng đột biến EGFR ở bệnh nhân ung thư phổi biểu mô tuyến. Đối tượng và phương pháp nghiên cứu: 114 bệnh nhân ung thư biểu mô tuyến của phổi giai đoạn IIIb, IV được chụp FDG PET/CT, xét nghiệm EGFR trước điều trị từ 11/2018 đến 07/2020. Kết quả: Độ tuổi trung bình 62,3± 8,4, tỷ lệ nam (63,2%) nữ (36,8%), giai đoạn IIIb (43,0%) và giai đoạn IV (57,0%). 43,0% bệnh nhân nghiên cứu không bộc lộ PD L1, 57,0% BN nghiên cứu có kết quả xét nghiệm PD L1 dương tính mức độ yếu đến mạnh.  Tỉ lệ đột biến gen EGFR và tỷ lệ không có đột biến tương ứng 55,3% và 44,7%. Giá trị SUVmax tại khối u phổi nguyên phát ở nhóm EGFR dương tính (11,2 ±5,7) thấp hơn có ý nghĩa thống kê so với nhóm EGFR âm tính (15,8±6,2) (p=0,04). Sử dụng biểu đồ ROC cho thấy, diện tích dưới đường cong (AUC) của SUVmax trong chẩn đoán EGFR dương tính là 0,654 (p<0,05). Kết hợp 4 yếu tố SUVmax, giới, tiền sử lá hút thuốc, cho kết quả chẩn đoán EGFR dương tính tốt hơn, cụ thể diện tích dưới đường cong (AUC) của 4 yếu tố là 0,706 (p<0,05). Kết luận: Đặc điểm FDG PET/CT có mối liên quan và có giá trị dự đoán tình trạng đột biến EGFR ở bệnh nhân ung thư biểu mô tuyến của phổi

The effects of chemotherapy on arterial inflammation assessed by 18 FDG PET-CT in patients with Lymphoma

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
E Solomou ◽  
I Koutagiar ◽  
N Ioakimidis ◽  
D Terentes-Printzios ◽  
A Georgakopoulos ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Heart Function ◽  
Specific Treatment ◽  
Chemotherapy Cycle ◽  
Treatment Regimes ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Study Population ◽  
Arterial Inflammation ◽  
Fdg Pet Ct

Abstract Introduction Anti-cancer treatment can lead to increased cardiovascular morbidity among lymphoma survivors. This may be the result of direct effect of treatment on heart function, or indirect acceleration of atherosclerosis. 18F-fluorodeoxyglucose (FDG) uptake is a sensitive and robust marker for assessment of atherosclerotic inflammation. Purpose To investigate the effects of chemotherapy on arterial inflammation using FDG-PET CT in patients with lymphoma. Methods Fifty nine (mean age 58±17 years) patients with Hodgkin (n=39) or non-Hodgkin lymphomas (n=20) underwent 18FDG PET-CT imaging at baseline, interim and after completion of chemotherapy as part of their routine protocol. Arterial inflammation was assessed by arterial target to background ratio (TBR) of the aortic wall along the entire aorta. The index vessel TBR (the vessel with the higher value at baseline) was used for assessment of arterial inflammation. Patients with Hodgkin Lymphomas (HL) underwent therapy with Doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD). The interim of their treatment was set at 1 to 3 days prior to initiating the 3rd chemotherapy cycle. Patients with non Hodgkin Lymphomas (NHL) underwent therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone+rituximab (R-CHOP). The interim of their treatment was set at 2 weeks post the 4th chemotherapy cycle. All patients we reassessed 6 weeks after chemotherapy completion. Results There were no differences in age and atherosclerotic risk factors (hypertension, diabetes, dyslipidemia and smoking), between the two groups (all P&gt;0.05). Similarly, there were no differences in mean (±SD) index vessel TBR between HL and NHL patients (2.4±0.7 vs 2.7±0.9, respectively, P=0.65). In the whole study population the index vessel TBR progressively decreased after the end of therapy (by 0.53±0.11, from baseline to 6 weeks following the end of therapies) (F=10.94, P&lt;0.001, ANOVA). The index vessel TBR decreased in both HL and NHL patients at 6 weeks after therapy compared to baseline level (all P&lt;0.01, ANOVA, figure). The decrease at the interim scan was more pronounced in NHL compared to HL patients, however at 6 weeks after chemotherapy completion the index vessel TBR decreased further in patients with HL, while it increased slightly compared to interim levels in NHL patients (figure 1). Conclusion Arterial inflammation is reduced during and post-chemotherapy in patients with lymphoma. The index vessel TBR changes at the interim phase and 6 weeks after therapy completion indicate a different effect of specific treatment regimes in arterial inflammation between HL and NHL patients. Figure 1 Funding Acknowledgement Type of funding source: None

scholarly journals The Pons As Region of Reference For Intensity Normalization In Semi-Quantitative Analysis of Brain 18FDG PET: Application to Metabolic Changes Related to Ageing in Conventional and Digital Control Databases

2021 ◽  
Author(s):  
Antoine Verger ◽  
Matthieu Doyen ◽  
Jacques-Yves Campion ◽  
Eric Guedj
Keyword(s):  
Fdg Pet ◽  
Correlation Coefficients ◽  
Metabolic Changes ◽  
18Fdg Pet ◽  
Median Correlation ◽  
Pet Ct ◽  
Digital Pet ◽  
Fdg Pet Ct ◽  
Intensity Normalization ◽  
Two Populations

Abstract Background: To define the most appropriate region for intensity normalization in brain 18FDG PET analysis through ageing.Brain metabolic changes related to ageing were evaluated in two populations of healthy controls who underwent conventional (n=56) or digital (n=78) 18FDG PET/CT. The median correlation coefficients between age and the metabolism of each 120 atlas brain region were reported for 120 distinct intensity normalizations (according to the 120 regions). SPM linear regression analyses with age were performed on most significant normalizations (FWE, p<0.05).Results: The cerebellum and pons were the two sole regions showing median coefficients of correlation with age less than -0.5. With SPM, the intensity normalization through the pons provided at least 1.7- and 2.5-fold more significant cluster volumes than other normalizations for conventional and digital PET respectively. Conclusions: The pons is the most appropriate area for brain 18FDG PET intensity normalization for examining the metabolic changes through ageing.

scholarly journals Diagnostic utility of 68Ga-citrate and 18FDG PET/CT in sarcoidosis patients

2020 ◽  
Vol 90 (4) ◽  
Author(s):  
Cuneyt Tetikkurt ◽  
Halil Yanardag ◽  
Burcak Haluk Sayman ◽  
Muammer Bilir ◽  
Seza Tetikkurt ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Fdg Pet ◽  
Emission Tomography ◽  
Organ Involvement ◽  
18Fdg Pet ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Sarcoidosis is a chronic granulomatous disease of unknown etiology. The disease  most commonly involves the lungs and the mediastinal lymph nodes while extrapulmonary organs such as the skin, eye, liver or spleen may also be comprised. Many imaging modalities have been used for the clinical evaluation of sarcoidosis patients but all have been found to have certain drawbacks for a reliable identification assessment due to the equivocal diagnostic results.  This case series was designed to determine the clinical trenchancy of simultaneous 68Ga citrate PET/CT [Positron emission tomography with 68Ga citrate (68Ga citrate PET/CT)] and 18F-FDG PET/CT [Positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT)] imaging in sarcoidosis patients. The main goal of the study was to evaluate sarcoidosis with respect to disease activity and organ involvement. A total of eight sarcoidosis patients with a comorbid disease suspicion were included in the study. Conventional clinical parameters used for  the diagnosis and the activity of sarcoidosis including CT [Computed tomography (CT)] were compared with the 68Ga-citrate PET/CT findings. Concurrent 18F-FDG PET/CT was performed to verify the granulomatous inflammation of sarcoidosis and to determine coexisting malignant or other inflammatory diseases. Our study results revealed that 68Ga citrate PET/CT imaging appears to be highly useful for the diagnosis, activity assessment and extrapulmonary organ involvement in sarcoidosis. Another crucial finding was the detection of extrapulmonary organ disease that are exceptionally involved, almost inaccessible by biopsy and that could not be otherwise displayed by other conventional imaging modalities. The third hallmark was the identification of a clinically asymptomatic and occult malignancy accompanying sarcoidosis that would not be revealed in any way if synchronous 18FDG PET/CT had not been performed. Simultaneous application of 68Ga citrate and 18FDG PET/CT may provide extremely useful data for the clinical evaluation of sarcoidosis patients in terms of the primary disease diagnosis, activity state, extrapulmonary organ involvement unachievable for biopsy and the clinically occult malignant disorders.

scholarly journals Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients

Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2361
Author(s):  
Umit Turan ◽  
Murat Aygun ◽  
Berna Bozkurt Duman ◽  
Aygül Polat Kelle ◽  
Yeliz Cavus ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Fdg Pet ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Node Metastasis ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Sensitivity Specificity ◽  
Fdg Pet Ct

Background: The aim of this study was to investigate the efficacy of post-neoadjuvant chemotherapy (NAC) ultrasound (US), magnetic resonance imaging (MRI), and F-18fluorodeoxyglucose positron emission tomography (F-18 FDG-PET/CT) for detecting post-NAC axillary lymph node(ALN) metastasis in patients who had ALN metastasis at the time of diagnosis. Methods: This study included all breast cancer patients who received NAC for ALN metastasis; underwent axillary assessment with US, MRI, or F18FDG-PET/CT; and then were operated on in the General Surgery Clinic, Adana City Research and Training Hospital, Turkey. Patients’ data were recorded, including demographic data, clinicopathological parameters, NAC regimens, and operation types. The axillary response to chemotherapy on post-NAC US, MRI, and F-18 FDG-PET/CT was compared with the postoperative histopathological result of the ALN. Results: The study included a total of 171 female patients. The mean age of the patients was 53.28 ± 10.62 years. The post-NAC assessment revealed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of US for detecting ALN metastasis were 59.42%, 82.35%, 82.00%, and 60.00%, respectively, while the same measures regarding MRI for detecting ALN metastasis were 36.67%, 77.78%, 73.33%, and 42.42%, respectively. The sensitivity, specificity, PPV, and NPV of F-18FDG-PET/CT were 47.50%, 76.67%, 73.08%, and 52.27%, respectively. The evaluation of dual combinations of these three imaging techniques showed that the specificity and PPV of the combined use of US and F-18FDG-PET/CT was 100%. Conclusions: The results showed that US has the highest sensitivity and specificity for detecting ALN metastasis after NAC. Furthermore, ALND may be preferred for these patients instead of SLNB if both examinations simultaneously indicate lymph node metastasis in the post-NAC assessment with US and F-18 FDG-PET/CT. SLNB may be preferred if these two examinations simultaneously show a complete response.

Assessment of early tumor response to induction chemotherapy (IC) in locally advanced squamous-cell carcinoma of head and neck (LASCCHN) with 18FDG PET-CT: A prospective trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6017-6017
Author(s):  
Ulisses Ribaldo Nicolau ◽  
Eduardo Nobrega Pereira Lima ◽  
Marclesson S. Alves ◽  
Thiago Bueno Oliveira ◽  
Victor Hugo Fonseca Jesus ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Locally Advanced ◽  
Prospective Trial ◽  
Disease Free Survival ◽  
Early Response ◽  
Response Evaluation ◽  
Who Criteria ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

6017 Background: Response to IC with triplet regimens adding taxanes to cisplatin and 5-fluorouracil (TPF), followed by chemoradiotherapy (CRT) for LASCCHN, is usually evaluated after 2 cycles of IC, based on bidimensional WHO or modified WHO criteria. Concerns regarding toxicity profile of TPF suggest a potential benefit of an early response evaluation approach that could select patients who would be spared from a toxic regimen and promptly started on an alternative treatment. The aim of this study is to assess the ability of evaluating early response after the first IC cycle based on a 40% decrease in standard-uptake value (SUV) measured by 18 FDG PET-CT on the 14th day. Methods: Patients with LASCCHN who underwent IC with TPF were prospectively evaluated. Staging procedure included locoregional and chest imaging, endoscopic examination and FDG PET-CT. At day 14 of first cycle, a second FDG PET-CT was performed and treating physicians were blinded for these findings. All cases were conducted according to the usual post-cycle 2 WHO or modified WHO criteria evaluation. Written informed consent was obtained from all recruited patients. Results: Between February 2010 and October 2012, 40 stage III/IV LASCCHN patients (34 oropharyngeal, 3 hypopharyngeal and 3 laryngeal) were recruited. With a median follow up of 11.4 months the actuarial 2 years overall (OS) and disease free survival (DFS) of all patients were 81.4% and 69.2%, respectively. Responders (any decrease of SUV) at day 14 PET CT had a better OS (90 vs. 27% - p<0,001) and DFS (76 vs. 0% - p<0,001) as compared to non-responders. Decrease of at least 40% in the SUV of primary tumor predicted a better DFS (100 vs. 51% - p=0,007). Conclusions: These results suggest a potential role of early response evaluation with 18 FDG PET-CT in patients with LASCCHN undergoing IC. A SUV decrease of at least 40% predicts better DFS. An increase in the SUV predicts a poor prognosis.

scholarly journals Der Beitrag der 18FDG-PET in der Entzündungsdiagnostik

2017 ◽  
Vol 40 (02) ◽  
pp. 119-133
Author(s):  
Martin Gotthardt ◽  
Anja Schlieck ◽  
James Nagarajah ◽  
Erik Aarntzen
Keyword(s):  
Fdg Pet ◽  
Low Dose ◽  
Wird Eine ◽  
Fieber Unklarer Genese ◽  
Low Dose Ct ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

ZusammenfassungDie 18FDG-PET/CT kann bei der Diagnostik entzündlicher Erkrankungen eine entscheidende Rolle spielen. Die PET/CT kombiniert die Möglichkeit der Ganzkörperaufnahme mit einer guten anatomischen Zuordnung von Befunden durch die simultan durchgeführte low dose CT. Sie ist daher eine exzellente Technik nicht nur für die Suche nach Entzündungsherden, sondern auch für die differenzialdiagnostische Unterscheidung von entzündlichen /Autoimmun-Erkrankungen und Tumorerkrankungen. Die hohe Sensitivität geht jedoch mit einer eher geringen Spezifität der FDG-Aufnahme einher. Daher ist die Erkennung bestimmter Muster und die korrekte Interpretation der Verteilung von Läsionen zusammen mit dem klinischen Kontext entscheidend für den Beitrag der FDG-PET/CT im Hinblick auf das klinische Management von Patienten. In dieser Arbeit wird eine Übersicht über die möglichen Ursachen und pathophysiologischen Mechanismen entzündlicher Erkrankungen (wie z. B. Sarkoidose, entzündliche Lungenerkrankungen, Osteomyelitis, Fieber unklarer Genese, Infektionen von Gefäßprothesen, Streuherde bei Infektionserkrankungen, etc.), sowie die damit verbundenen typischen Muster der FDG-Anreicherung gegeben. Weiterhin werden Differenzialdiagnosen diskutiert und Hinweise zur optimalen Bildinterpretation gegeben.

scholarly journals Η συμβολή της ποζιτρονίκης υπολογιστικής τομογραφίας με 18-φθόριο-δεσοξυ-γλυκόζη, [18FDG-PET/CT) στη διαχείριση ασθενών με μυελοειδή καρκίνο του θυεροειδούς αδένα

2013 ◽  
Author(s):  
Ευαγγελία Σκούρα
Keyword(s):  
Fdg Pet ◽  
18Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Σκοπός: Η μέτρηση της καλσιτονίνης είναι σημαντική στην παρακολούθηση ασθενών με μυελοειδή καρκίνο του θυρεοειδούς αδένα (ΜΚΘ). Σκοπός της μελέτης είναι η διερεύνηση της διαγνωστικής ακρίβειας της [18F]FDG-PET/CT σε ασθενείς με ΜΚΘ και αυξημένη τιμή καλσιτονίνης μετά τη θυρεοειδεκτομή και η αναγνώριση πιθανής συσχέτισης της ευαισθησίας της [18F]FDG-PET/CT με τα επίπεδα της καλσιτονίνης.Υλικό-Μέθοδοι: Από το Φεβρουάριο 2007 έως τον Αύγουστο του 2012 πραγματοποιήθηκαν 59 [18F]FDG-PET/CT εξετάσεις σε 51 ασθενείς με γνωστό, επιβεβαιωμένο ιστολογικά ΜΚΘ και αυξημένα επίπεδα καλσιτονίνης μετά την αρχική χειρουργική επέμβαση, προκειμένου να ανιχνευθούν οι εστίες υποτροπής. Η ομάδα των ασθενών περιελάμβανε 15 άνδρες και 36 γυναίκες, ηλικίας 12-79 ετών. Από τους ασθενείς, 18 είχαν κληρονομική μορφή ΜΚΘ και συγκεκριμένα 7 οικογενή και 11 ως εκδήλωση του ΜΕΝ ΙΙΑ συνδρόμου, ενώ 33 είχαν σποραδικό ΜΚΘ. Όλοι οι ασθενείς είχαν υποβληθεί εντός των προηγούμενων 4 εβδομάδων, σε τουλάχιστον μια επιπλέον απεικονιστική μέθοδο, με αποτελέσματα όμως αρνητικά ή αμφίβολα.Αποτελέσματα: Ως προς τα αποτελέσματα υπήρχαν 29 θετικές και 30 αρνητικές [18F]FDG-PET/CT εξετάσεις. Η συνολική ευαισθησία της [18F]FDG-PET/CT ήταν 44.1% στην ανίχνευση εστιών ΜΚΘ σε ασθενείς με αυξημένα επίπεδα καλσιτονίνης ορού και αρνητικό ή αμφίβολο το λοιπό συμβατικό απεικονιστικό έλεγχο. Μετά από διαίρεση των εξετάσεων που πραγματοποιήθηκαν, με βάση τα επίπεδα της καλσιτονίνης, στις περιπτώσεις με καλσιτονίνη έως 1000pg/ml η ευαισθησία ήταν μόλις 29.5% ενώ στις περιπτώσεις με επίπεδα καλσιτονίνης >1000pg/ml ήταν πολύ μεγαλύτερη, της τάξεως του 86.7%. Ενδιαφέρον εύρημα της μελέτης ήταν ότι η ευαισθησία της [18F]FDG-PET/CT στους ασθενείς με σύνδρομο ΜΕΝΙΙΑ ήταν χαμηλότερη με τιμή 23%. Όταν εξαιρέσαμε από τους υπολογισμούς μας τις περιπτώσεις με σύνδρομο ΜΕΝ ΙΙΑ, τότε η συνολική ευαισθησία της [18F]FDG-PET/CT στην ανίχνευση εστιών ΜΚΘ αυξήθηκε στο 50% και στις περιπτώσεις με επίπεδα καλσιτονίνης >1000pg/ml το ποσοστό έφτασε στο 100%. Συμπεράσματα: Τα ευρήματα της μελέτης δείχνουν ότι η εξέταση [18F]FDG-PET/CT φαίνεται να είναι πολύτιμο εργαλείο για την ανίχνευση υποτροπής σε ασθενείς με ΜΚΘ και πολύ αυξημένα επίπεδα καλσιτονίνης, >1000pg/ml, ενώ δεν φαίνεται να ισχύει το ίδιο για περιπτώσεις με χαμηλότερες τιμές καλσιτονίνης. Επίσης, φαίνεται ότι η ευαισθησία της [18F]FDG-PET/CT είναι χαμηλότερη σε ασθενείς με ΜΚΘ στα πλαίσια του συνδρόμου MEN IIA.

scholarly journals 18FDG-PET/CT findings in COVID-19: a single centre retrospective radiological review

2020 ◽  
Vol 6 (3) ◽  
pp. 20200091 ◽  
Author(s):  
Pia F. P. Charters ◽  
David Little ◽  
Jonathan C. L. Rodrigues ◽  
Richard N Graham ◽  
Stewart L Redman
Keyword(s):  
Fdg Pet ◽  
Low Dose ◽  
Single Centre ◽  
Global Pandemic ◽  
18Fdg Pet ◽  
Clinical Scenarios ◽  
Pet Ct ◽  
The Uk ◽  
Fdg Pet Ct ◽  
Local Protocol

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the infectious disease COVID-19, was declared a global pandemic in March 2020. As radiology departments recommence 18FDG-PET/CT imaging, it is likely that both asymptomatic and specific symptomatic patients with COVID-19 infection will be imaged, particularly if the disease becomes endemic in the UK. We review the clinical scenarios where 18FDG-PET/CT could be performed in COVID-19 positive patients. Our local protocol for safely scanning known COVID-19 positive patients is described, highlighting considerations for other departments. We present the findings from a series of known COVID-19 positive patients and two further asymptomatic cases evaluated with18FDG-PET/CT. Classic, indeterminate, normal and non-COVID-19 manifestations on both the 18FDG-PETand low dose CT component are described as an aid for radiologists and nuclear medicine physicians when reporting 18FDG PET/CT.

scholarly journals Evaluation of radiographic and metabolic changes in bone metastases in response to systemic therapy with 18FDG-PET/CT

2015 ◽  
Vol 49 (2) ◽  
pp. 115-120 ◽  
Author(s):  
Bengul Gunalp ◽  
Ali Ozan Oner ◽  
Semra Ince ◽  
Engin Alagoz ◽  
Aslı Ayan ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Metabolic Activity ◽  
Systemic Therapy ◽  
Fdg Pet ◽  
Therapy Response ◽  
Metabolic Changes ◽  
Metabolic Characteristics ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Fdg Pet Ct

Abstract Background. The aim of the study was to retrospectively evaluate radiographic and metabolic changes in bone metastases in response to systemic therapy with 18FDG-PET/CT and determine their roles on the evaluation of therapy response. Patients and methods. We retrospectively evaluated radiographic and metabolic characteristics of bone metastases in 30 patients who were referred for the evaluation of response to systemic therapy with 18FDG-PET/CT. All patients underwent integrated 18FDG-PET/CT before and after treatment. Results. The baseline radiographic patterns of the target lesions in responders group were lytic, sclerotic, mixed and CT negative; after treatment the radiographic patterns of all target lesions changed to a sclerotic pattern and attenuation increased (p = 0.012) and metabolic activity decreased (p = 0.012). A correlation was found between decreasing metabolic activity and increasing attenuation of the target lesions (r = -0.55) (p = 0.026). Ho wever, in nonresponders group, the baseline radiologic patterns of the target lesions were lytic, blastic, mixed and CT negative; after treatment all lytic target lesions remained the same and one CT negative lesion turned to lytic pattern and the attenuation of the target lesions decreased (p ± 0.12) and metabolic activity increased (p = 0.012). A correlation was found between increasing metabolic activity and decreasing attenuation (r = -0.65) (p = 0.032). An exception of this rule was seen in baseline blastic metastases which progressed with increasing in size, metabolic activity and attenuation. Conclusions. This study shows that the metabolic activity of lesions is a more reliable parameter than the radiographic patterns for the evaluation of therapy response.

scholarly journals Role of PET-CT in Aiding Diagnosis of Various Neurological Conditions – A Case Series

2021 ◽  
Vol 10 (7) ◽  
pp. 440-446
Author(s):  
Harleen Singh Pabla ◽  
Gokulakrishnan P.R. ◽  
Arunan Murali ◽  
Venkata Sai P.M.
Keyword(s):  
Metabolic Activity ◽  
Fdg Pet ◽  
Caudate Nuclei ◽  
Fdg Uptake ◽  
18Fdg Pet ◽  
Pet Ct ◽  
Neurological Conditions ◽  
Fdg Pet Ct ◽  
The Brain

BACKGROUND PET-CT is an imaging modality which electronically detects positron-emitting radiopharmaceuticals in the human body and reveals its exact anatomical location.1 PET CT measures the metabolic and functional activity of living tissue noninvasively.1 This technology is utilized in diagnosis, planning treatment and predicting outcomes in various neurological conditions.1 Depending upon various patterns of FDG uptake in different parts of brain, 18FDG PET-CT allows us to differentiate between various types of dementia.2 PET CT allows tracking the course of disease and revealing the severity of the disease.2 In this article, we discuss the imaging findings of normal 18 FDG PET-CT of brain and 8 different neurological conditions with their corresponding brain PET-CT findings. METHODS To study the role of 18FDG-PET/CT in neurological conditions, we identified 8 different patients who underwent 18FDG-PET/CT imaging of brain for clinically suspected different neurological diseases at Department of Radiodiagnosis-Centre of Excellence (CERIS), SRIHER, Chennai, between 2015 and 2019. Siemens Biograph Horizon 16-slice PET/CT scanner with TrueV was used. Syngo.Via Version VB30A software was used. 18F- Fluorodeoxyglucose was the radiotracer used [Dose: 3-7 mCi]. After the scan, different patterns of 18 FDG uptake in the brain were analyzed in each of these patients. RESULTS 18 FDG PET-CT showed reduced uptake in the epileptogenic foci in the brain. Alzheimer’s disease showed decreased FDG uptake in bilateral precuneus, posterior cingulate region, parietal cortex and frontal cortex. Fronto-temporal dementia revealed reduced FDG uptake in anterior cingulate gyrus and anterior temporal lobe. Primary progressive aphasia showed asymmetrical reduced metabolic activity in the bilateral frontal and temporal lobes. Progressive supranuclear palsy revealed reduced metabolic activity in bilateral paramedian frontal region, head of caudate nuclei and midbrain; Multi systemic atrophy showed reduced metabolic activity in midbrain, pons, medulla oblongata and the cerebellum; AIDS related dementia showed global hypometabolism with preserved uptake in basal ganglia. CONCLUSIONS 18FDG-PET/CT has a vital complementary role in the evaluation CNS disorders along with clinical examination, other imaging modalities like CT, MRI, and electroencephalogram (EEG). Radiologists should be aware of these different patterns of FDG uptake to aid the clinical diagnosis and early treatment. KEY WORDS 18 FDG PET-CT, 18FDG Uptake, Hypometabolism, PET-CT Brain

Sign in / Sign up

Export Citation Format

Share Document